This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy International
See you next year! September 15-18, 2025
Hynes Convention CenterBoston, MA

Jack Crawford
CEO at Demeetra
Speaker

Profile

Jack Crawford is the founding CEO of Demeetra. As CEO, Jack is focused on providing partners with commercially applicable gene editing technologies through simple accessible licenses. Prior to Demeetra, he was at Hera BioLabs, where he successfully led a complete business pivot to spear-heading the first fully immunodeficient gene edited rat models for oncology xenografts. While serving as VP of Business Development at Transposagen, Jack was instrumental in laying the foundation for commercial applications of the piggyBac transposase, a widely adopted gene editing technology. Mr. Crawford holds a BS in Biochemistry from Virginia Tech and a Master's in Biotechnology from University of Pennsylvania.

Jack Crawford's Network

Agenda Sessions

  • Undeniable CRISPR FTO: Combining Cas-CLOVER IP with Foundational CRISPR/Cas9 IP from the CVC

    4:50pm